Overview
- Peptide (C)RRSIHSVGLTGDSHS, corresponding to amino acid residues 315 -329 of rat GPR26 (Accession Q9QXI3). Intracellular, C-terminus.
GPR26 Blocking Peptide (#BLP-GR066)
Western blot analysis of rat DRG lysate (lanes 1 and 4), rat brain lysate (lanes 2 and 5), and mouse brain lysate (lanes 3 and 6):1-3. Anti-GPR26 Antibody (#AGR-066), (1:200).
4-6. Anti-GPR26 Antibody (#AGR-066), preincubated with GPR26 Blocking Peptide (#BLP-GR066).
Western blot analysis of human SH-SY5Y neuroblastoma cell:1. Anti-GPR26 Antibody (#AGR-066), (1:200).
2. Anti-GPR26 Antibody (#AGR-066), preincubated with GPR26 Blocking Peptide (#BLP-GR066).
Expression of GPR26 in mouse olfactory bulb:Immunohistochemical staining of perfusion-fixed frozen mouse olfactory bulb using Anti-GPR26 Antibody (#AGR-066), (1:300), followed by goat anti-rabbit-AlexaFluor-488. A. There was intense GPR26 immunoreactivity (green) in the external plexiform layer (EPL), and moderate intensity in the glomerulus (G). B. Pre-incubation of the antibody with GPR26 Blocking Peptide (BLP-GR066), suppressed staining. Cell nuclei are stained with DAPI (blue).
Expression of GPR26 in mouse deep cerebellar nuclei:Immunohistochemical staining of perfusion-fixed frozen mouse brain sections using Anti-GPR26 Antibody (#AGR-066), (1:300), followed by goat anti-rabbit-AlexaFluor-488. A. GPR26 immunoreactivity (green) appears in neuronal profiles (arrows). B. Pre-incubation of the antibody with GPR26 Blocking Peptide (BLP-GR066), suppressed staining. Cell nuclei are stained with DAPI (blue).
- Boulay, J.-L. et al. (2009) Int. J. Oncol., 35, 1123–1131.
- Chen, D. et al. (2012) PLoS ONE, 7, e40764.
- Jones, P. G. et al. (2007) Biochim. Biophys. Acta, 1770, 890–901.
- Mori, F. et al. (2016) Neuropathology, 36, 50–55.
- Zhang, L.-L. et al. (2011) Neuroscience, 196, 203–214.
GPR26, also known as G protein-coupled receptor 26, is part of the extensive G protein-coupled receptor (GPCR) superfamily, characterized by seven transmembrane domains¹. These receptors primarily mediate cellular responses to various extracellular signals, such as hormones and neurotransmitters, by coupling with intracellular G proteins, leading to signal transduction cascades1,3.
GPR26 exhibits high basal activity, stimulating cyclic AMP (cAMP) production in an agonist-independent manner3. It is predominantly expressed in the central nervous system, particularly in the hypothalamus, amygdala, cortex, and striatum3,5. Cellularly, it localizes to neurons and is involved in central nervous system processes2,4. Functionally, GPR26 modulates energy balance via hypothalamic AMPK signaling and influences mood regulation by phosphorylating CREB in the amygdala2,5.
Inactivation of GPR26 in animal models demonstrates its role in obesity, anxiety, and depression. In vitro, its loss enhances hypothalamic activity, causing hyperphagia and metabolic dysregulation, while in vivo, it leads to reduced phosphorylated CREB levels, contributing to anxiety and depression-like behaviors2,5.
Aberrant GPR26 function is implicated in glioblastomas due to epigenetic silencing, linking it to tumorigenesis1. It is also associated with neurodegenerative diseases, where it participates in intranuclear inclusion formation in neurons and glial cells4.
Research on GPR26 benefits areas like neuropsychiatric disorders, metabolic diseases, cancer, and neurodegeneration, where its detection and functional studies may inform therapeutic developments1,3.
Anti-GPR26 Antibody (#AGR-066) is a highly specific antibody directed against an epitope of the rat protein. The antibody can be used in western blot and immunohistochemistry applications. It has been designed to recognize GPR26 from rat, mouse and human samples.
Powered by Bioz
